A total of 34 HCC patients with complete clinical and experimental data were evenly divided into two groups on the basis of the median value of the percentage of FOXP3+ cells in the CD3+CD56+ population in TILs as the cut-off point (Supplementary Table S1). This evidence concerns the gene NCAM1 and hepatocellular carcinoma.